Lapatinib, an oral tyrosine kinase inhibitor, is currently part of a second-line treatment plan for metastatic HER2+ breast cancer patients who have already had treatment with an antibody- and chemotherapy-based regimen. Here, ERBB2 is linked to breast cancer.